Replimune (REPL) Cash & Equivalents (2018 - 2026)

Replimune has reported Cash & Equivalents for 9 years, with the latest figure at $209.0 million in Q1 2026.

• Quarterly Cash & Equivalents rose 88.11% year-over-year to $209.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $209.0 million (up 88.11% YoY) and the FY2026 annual result came in at $209.0 million, up 88.11% from the prior year.
• Cash & Equivalents climbed to $209.0 million in Q1 2026 per REPL's latest filing, from $123.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $209.0 million in Q1 2026 and troughed at $74.5 million in Q1 2024.
• A 5-year average of $121.4 million and a median of $111.1 million in 2025 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 95.19% in 2023, down 52.74% in 2023.
• Over 5 years, Cash & Equivalents stood at $206.7 million in 2022, then slumped by 52.74% to $97.7 million in 2023, then jumped by 76.35% to $172.2 million in 2024, then retreated by 28.62% to $123.0 million in 2025, then soared by 70.01% to $209.0 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $209.0 million, $123.0 million, and $102.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.